Appalachian Tri-State Node

阿巴拉契亚三州节点

• 批准号: 8320384
• 负责人: DENNIS C DALEY
• 金额: $ 106.37万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8320384
• 关键词: Address; Adoption; Behavioral; Clinic; Clinical; Clinical Trials; Clinical Trials Network; Communities; Comorbidity; Conduct Clinical Trials; Country; DA10; Drug abuse; Education; Effectiveness; Effectiveness of Interventions; Ensure; Evidence based treatment; Family; Funding; Future; Goals; HIV; Health Personnel; High Prevalence; Housing; Institutes; Intervention; Location; Manuals; Medical; Medicine; Mental Health; Meridians; Mission; Multi-Institutional Clinical Trial; National Institute of Drug Abuse; Office of Administrative Management; Patients; Pharmaceutical Preparations; Physicians; Population; Primary Health Care; Principal Investigator; Progress Reports; Protocols documentation; Provider; Psychiatric therapeutic procedure; Randomized; Research; Research Infrastructure; Research Training; Science; Screening procedure; Services; Site; Substance Use Disorder; System; Training; Training Programs; Treatment outcome; Work; Writing; addiction; community based treatment; cost; cost effectiveness; dissemination research; improved; lectures; meetings; patient population; protocol development; public health relevance; response; symposium; working group

DESCRIPTION (provided by applicant): This is a competing renewal application by the Appalachian Tri-State (ATS) Node of NIDA's Clinical Trials Network (CTN) in response to RFA-DA-10-009. During the previous funding period, the ATS Node made substantial contributions to CTN research, dissemination and administrative activities. We collaborated effectively with NIDA, other Nodes and community treatment providers (CTPs) in advancing the mission of the CTN by: 1) participating in four clinical trials and preparing for a fifth; 2) contributing to new protocols under review; 3) writing a treatment manual for a trial; 4) developing and delivering clinical training protocols and fidelity scales for experimental interventions; 5) disseminating information about NIDA Evidenced-Based Treatments (EBTs) through lectures, training programs, conferences, writings for professionals and writings for patients with drug problems; and 6) participating in CTN committees, work groups and national and regional dissemination conference planning committees. Four new CTN trials were implemented during the past 4 years and ATS was one of three CTN Nodes that participated in all four, having excellent subject recruitment for three of four CTN studies by exceeding our original recruitment goals by randomizing 255 subjects in these trials. In response to the changing research needs of NIDA to conduct clinical trials in non-addiction treatment settings, the ATS node expanded our CTPs to include medical and psychiatric systems and an HIV primary care clinic. To demonstrate our ability to contribute conceptually to future CTN projects, we propose a research agenda that focuses on studies of substance use disorders (SUDs) that co-occur with psychiatric and/or medical conditions. Studies of co-occurring medical and mental health conditions are needed because of the high prevalence of SUDs among those who have other illnesses and the lack of studies for many specialized clinical populations, especially patients in medical settings. Potential CTN studies could focus on screening, identifying and engaging patients with SUDs in these non-addiction settings as well as examining dissemination and cost-effectiveness of the interventions. PUBLIC HEALTH RELEVANCE: The funded application will improve the quality of drug abuse treatment throughout the country by conducting studies of behavioral, pharmacological, and integrated treatment interventions in rigorous, multi-site clinical trials to determine effectiveness across a broad range of treatment settings and diversified patient populations; and to ensuring the transfer of research results to physicians, clinicians, providers, and patients.

描述（由申请人提供）：这是NIDA临床试验网络（CTN）的Appalachian三州（ATS）节点响应RFA-DA-10-009的竞争性续期申请。在上一个供资期间，ATS节点对CTN的研究、传播和行政活动作出了重大贡献。我们与NIDA、其他节点和社区治疗提供商（ctp）进行了有效合作，通过以下方式推进CTN的使命：1)参与了四项临床试验，并准备进行第五项临床试验；2)为正在审查的新协议作出贡献；3)为试验编写治疗手册；4)为实验性干预制定和提供临床培训方案和保真度量表；5)通过讲座、培训计划、会议、专业人士写作和药物问题患者写作等方式传播NIDA循证治疗（ebt）的信息；6)参加CTN各委员会、工作组以及国家和地区传播会议规划委员会。在过去的4年中实施了4项新的CTN试验，ATS是参与所有4项CTN试验的三个CTN节点之一，通过在这些试验中随机分配255名受试者，在4项CTN研究中有3项获得了出色的受试者招募，超出了我们最初的招募目标。为了响应NIDA不断变化的研究需求，在非成瘾治疗环境中进行临床试验，ATS节点扩大了我们的ctp，包括医疗和精神病学系统以及艾滋病毒初级保健诊所。为了证明我们有能力在概念上为未来的CTN项目做出贡献，我们提出了一个研究议程，重点研究与精神和/或医学状况共同发生的物质使用障碍（sud）。由于在患有其他疾病的人群中，sud的患病率很高，而且缺乏对许多专业临床人群，特别是医疗环境中的患者的研究，因此需要对同时发生的医疗和精神健康状况进行研究。潜在的CTN研究可以侧重于筛查、识别和参与这些非成瘾环境中的sud患者，以及检查干预措施的传播和成本效益。